Multiplex Serology — Why It Matters for Vaccine Development

Vaccine immunogenicity assessment requires measuring antibody responses to each antigen in the formulation — a quadrivalent influenza vaccine demands four separate strain-specific HA measurements; RSV vaccine development requires quantifying responses to the pre-fusion F conformation central to neutralizing activity; mpox/smallpox vaccination programs need to distinguish responses to multiple orthopoxvirus antigens. Running individual ELISAs for each antigen consumes sample, time, and resources — while introducing inter-assay CV that complicates strain-to-strain comparison. Multiplex serology on MSD addresses all three: 6 flu strains in one well, with internal normalization eliminating cross-well variability, from 25 µL total. For multi-year vaccine development programs, V-PLEX lot-to-lot bridging ensures antibody titers remain analytically comparable across the entire clinical development timeline.

Advantages of Multiplex Serology for Vaccine Research

  • Strain-to-strain comparison without cross-assay variability: when six HA antibody responses are measured in the same well, relative responses between strains are internally normalized — eliminating the inter-assay CV that clouds comparison when measured in six separate ELISA wells.
  • 25 µL for comprehensive serology: a full 6-strain influenza panel consumes less sample than a single ELISA well. For pediatric vaccine research, field epidemiology with finger-stick samples, and serial NHP sampling, this volume efficiency is transformative.
  • V-PLEX lot-bridging for multi-year programs: vaccine development spans years from Phase I through Phase III and post-licensure. V-PLEX reagent lot bridging ensures antibody titers measured in Year 1 are analytically comparable to Year 3.
  • Simultaneous antibody isotype detection: SULFO-TAG-labeled anti-IgG, anti-IgM, or anti-IgA detection reagents enable isotype-specific serology from the same antigen panel — distinguishing acute (IgM) from memory (IgG) responses or assessing mucosal (IgA) vaccine responses.